Monte Rosa Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Monte Rosa Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($27.08M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($12.30M) | Aug 7, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($12.30M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | $46.89M | May 8, 2025 |
| Q2 | 2025 | Mar 31, 2025 | $46.89M | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | $46.89M | Nov 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($23.86M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($30.31M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($30.31M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($31.97M) | May 8, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($31.97M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($31.97M) | Nov 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($34.88M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($35.18M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($35.18M) | Nov 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($32.04M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($32.04M) | Aug 8, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($32.04M) | Nov 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($27.32M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($26.47M) | Aug 10, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($32.98M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($15.55M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | $44.04M | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($26.53M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($32.64M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($34.95M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($36.97M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($37.22M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($34.26M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($28.36M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($27.23M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($24.30M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($19.87M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($18.12M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($11.50M) | May 11, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($6.39M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($5.40M) | Aug 12, 2021 |